Saltar al contenido
Merck

F9302

Sigma-Aldrich

Factor X Activated (Xa) from bovine plasma

aqueous glycerol solution

Sinónimos:

Factor Xa

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número de CAS:
Comisión internacional de enzimas:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.54

form

aqueous glycerol solution

Quality Level

specific activity

≥50 units/mg protein

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

cow ... F10(280787)

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Fusion proteins are commonly expressed with a factor Xa cleavable Ile-Glu (or Asp)-Gly-Arg-↓-X sequence. Typically 1 mg of fusion protein can be incubated with 10 μg of factor Xa for 2.5 hours at 37 °C.

Biochem/physiol Actions

Factor Xa catalyzes the hydrolysis of the Arg-Thr and then Arg-Ile bonds in prothrombin to yield active thrombin.
The fairly strict recognition sequence is Ile-Glu (or Asp)-Gly-Arg-↓-X.
It may sometimes cleave at other basic residues, depending on the conformation of the target protein. Factor Xa will not cleave if a proline residue follows the arginine of the recognition sequence.
pH Optimum: 7.6-8.0
Temperature Optimum: 37 °C

Physical properties

Factor Xa is a serine endoproteinase and a member of the S1 peptidase family. Factor Xa plays a critical role in the coagulation cascade by catalyzing the proteolytic conversion of prothrombin to active thrombin. Factor Xa′s prothrombin conversion activity is greatly enhanced in vivo when complexed with factor V, calcium ions and phospholipids on the activated platelet surface.
The zymogen form, Factor X, is activated in vivo by two different pathways. The intrinsic pathway utilizes a catalytic complex composed of factor IXa, factor VIII, phospholipids and calcium ions. The extrinsic pathway utilizes a complex of factor VII and tissue factor. The factor X zymogen is a 55 KDa glycoprotein with a light and heavy chain joined by a single disulfide.

Unit Definition

One unit of activated Factor X will liberate 1.0 μmole of p-nitroanilide from N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginine-p-nitroaniline per minute at pH 8.3 at 37 °C.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

substrate

Referencia del producto
Descripción
Precios

Storage Class

10 - Combustible liquids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
The Medical letter on drugs and therapeutics, 55(1409), 9-10 (2013-02-06)
Doron Bushi et al.
Journal of neuroscience research, 96(8), 1406-1411 (2018-05-16)
Factor Xa (FXa) plays a critical role in the coagulation cascade by generation of thrombin. During focal ischemia thrombin levels increase in the brain tissue and cause neural damage. This study examined the hypothesis that administration of the FXa inhibitor
[Xarelto: other advantages].
Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec, 10(1), 59-59 (2013-02-06)
Taki Galanis et al.
Hospital practice (1995), 41(1), 26-36 (2013-03-08)
Nonvalvular atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia occurring in patients in the United States. The primary clinical consequence of AF is an increase in the risk and severity of strokes. Treatment guidelines recommend anticoagulation therapy
Alexander T Cohen et al.
The New England journal of medicine, 368(6), 513-523 (2013-02-08)
The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico